Clinical Trial: Beta-CIT-SPECT and Neurophysiology in Depression

This study is currently recruiting patients.
Verified by Ludwig-Maximilians-University, Munich, Germany September 2005

Sponsors and Collaborators: Ludwig-Maximilians-University, Munich, Germany
H. Lundbeck A/S
Information provided by: Ludwig-Maximilians-University, Munich, Germany
ClinicalTrials.gov Identifier: NCT00145132

Purpose

Aim of this project is to investigate the effects of escitalopram on monoamine transporter (SERT, DAT) availabilities as assessed by b-CIT and SPECT, and on neurophysiological parameters such as the loudness dependence of auditory evoked potentials (LDAEP) in patients with depression.
Condition Intervention Phase
Depression
 Procedure: β-CIT-SPECT, Neurophysiology
Phase IV

MedlinePlus related topics:  Depression

Study Type: Interventional
Study Design: Diagnostic, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacodynamics Study

Official Title: Serotonin and Dopamine Transporter (SERT, DAT) Availabilities as Assessed by b-CIT and SPECT, and Neurophysiological Measures of Central Serotonergic Activity in Patients with Depression Under Treatment with Escitalopram

Further Study Details: 
Primary Outcomes: changes in β-CIT/neurophysiological measurements from baseline to week 4
Expected Total Enrollment:  30

Study start: June 2005

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both
Criteria

Inclusion Criteria:

  • Psychiatric in or outpatients with acute depressive episode
  • Indication for pharmacological treatment

Exclusion Criteria:

  • Acute suicidality
  • Neurological or severe somatic disorders
  • Occupational exposition to radiation >15 mSv per year
  • Women during pregnancy or lactation

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00145132

Oliver Pogarell, MD      +49 89 5160  Ext. 3409    oliver.pogarell@med.uni-muenchen.de

Germany
      Depts. of Psychiatry and Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich,  D-80336,  Germany; Recruiting
Oliver Pogarell, MD  +49 89 5160  Ext. 3409    oliver.pogarell@med.uni-muenchen.de 
Klaus Tatsch, MD  +49 89 7095  Ext. 4650    klaus.tatsch@med.uni-muenchen.de 
Oliver Pogarell, MD,  Principal Investigator
Klaus Tatsch, MD,  Principal Investigator

Study chairs or principal investigators

Oliver Pogarell, MD,  Principal Investigator,  Dept. of Psychiatry, University of Munich   

More Information

Study ID Numbers:  ESCIT-SPECT-Pogarell
Last Updated:  September 2, 2005
Record first received:  September 1, 2005
ClinicalTrials.gov Identifier:  NCT00145132
Health Authority: Germany: Federal Institute for Drugs and Medicinal Devices
ClinicalTrials.gov processed this record on 2005-09-06



Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us